EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction



Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction



Journal of Allergy & Clinical Immunology 104(3 PART 1): 547-553, Sept



Background: Montelukast, a leukotriene receptor antagonist, and salmeterol, a long-acting beta2-receptor agonist, each have demonstrated benefits in the treatment of exercise-induced bronchoconstriction (EIB) in short-term studies. Direct comparisons between these agents in long-term studies are limited. Objective: We sought to compare montelukast and salmeterol in the long-term treatment of EIB. Methods: One hundred ninety-seven patients with mild asthma and a postexercise fall in FEV1 of at least 18% were randomized (double-blind) to receive montelukast 10 mg once daily or salmeterol 50 mug twice daily for 8 weeks. Exercise challenge was repeated at day 3, week 4, and week 8 after randomization near the end of the dosing interval for both drugs. The primary efficacy endpoint was the maximal percent fall in postexercise FEV1 at week 8. Results: Montelukast was effective in treating EIB without inducing tolerance and provided superior (P ltoreq .001) protection than salmeterol at weeks4 and 8, with comparable protection at day 3. The frequency of respiratory clinical adverse events (P = .046) and discontinuations because of clinical adverse events (P = .052) were less with montelukast. Conclusion: The effect of montelukast was greater than that of salmeterol in the chronic treatment of EIB over a period of 8 weeks in patients with mild asthma as demonstrated by effect size, maintenance of effect, and fewer respiratory clinical adverse events during the study period. Montelukast may be a better alternative to salmeterol as a controller agent for the chronic treatment of EIB.

(PDF emailed within 0-6 h: $19.90)

Accession: 011014638

Download citation: RISBibTeXText

DOI: 10.1016/s0091-6749(99)70322-2



Related references

Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. Journal of Allergy and Clinical Immunology 104(3 Pt 1): 547-553, 1999

Oral montelukast versus inhaled salmeterol to prevent exercise-induced bronchoconstriction. Annals of Internal Medicine 133(5): 392; Author Reply 392-3, 2000

Effects of montelukast and salmeterol on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction. Chest 126(4): 1154-1160, 2004

Prevention of exercise-induced bronchoconstriction by a single dose of montelukast or salmeterol. Journal of Allergy and Clinical Immunology 119(1-supp-S), 2007

Single-dose montelukast or salmeterol as protection against exercise-induced bronchoconstriction. Chest 132(3): 875-883, 2007

Effect of montelukast or salmeterol added to inhaled fluticasone on exercise-induced bronchoconstriction in children. Annals of Allergy, Asthma & Immunology 104(6): 511-517, 2010

Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction: A randomized, double-blind trial. Annals of Internal Medicine 132(2): 97-104, Jan 18, 2000

Montelukast compared to salmeterol in the treatment of exercise-induced asthma. European Respiratory Journal 12(SUPPL 28): 361S, Sept, 1998

Montelukast improves patient global assessment and decreases beta-agonist requirements in patients with mild asthma and exercise-induced bronchoconstriction. European Respiratory Journal Supplement 10(25): 438S, Sept, 1997

Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Allergy (Copenhagen) 56(Supplement 68): 167, 2001

Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clinical & Experimental Allergy 32(9): 1360-1365, September, 2002

Comparison of oral Montelukast, a leukotriene antagonist and inhaled Salmeterol in exercise induced asthma. European Respiratory Journal 12(Supplement 29): 18s, December, 1998

Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. Journal Of Pediatrics. 133(3): 424-428,., 1998

Oral montelukast versus inhaled salmeterol to prevent exercise-induced bonchonconstriction. Annals of Internal Medicine 133(5): 392; Author Reply 392-3, 2000